Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"
- PMID: 32950695
- DOI: 10.1016/j.bbmt.2020.08.032
Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"
Comment in
-
Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".Biol Blood Marrow Transplant. 2020 Dec;26(12):e335-e336. doi: 10.1016/j.bbmt.2020.09.009. Epub 2020 Sep 18. Biol Blood Marrow Transplant. 2020. PMID: 32950694 No abstract available.
Comment on
-
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.Biol Blood Marrow Transplant. 2020 Sep;26(9):1581-1588. doi: 10.1016/j.bbmt.2020.06.008. Epub 2020 Jun 17. Biol Blood Marrow Transplant. 2020. PMID: 32561336
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
